Human Growth Hormone ( DrugBank: Growth hormone, Human growth hormone )

4 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
78	下垂体前葉機能低下症	184
187	歌舞伎症候群	1
193	プラダー・ウィリ症候群	3
265	脂肪萎縮症	12

78. 下垂体前葉機能低下症

臨床試験数 : 494 / 薬物数 : 385 - (DrugBank : 49) / 標的遺伝子数 : 44 - 標的パスウェイ数 : 100

diseases per page:

Showing 1 to 10 of 184 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2020-000929-42-BG (EUCTR)	07/01/2022	20/01/2021	Trial to compare the efficacy and safety of once-weekly lonapegsomatropin with placebo and a daily s ...	foresiGHt: A multicenter, randomized, parallel-arm, placebo- controlled (double- blind) and active-c ...	Adult Growth Hormone Deficiency (AGHD) MedDRA version: 20.0;Level: PT;Classification code 10056438;T ...	Product Name: lonapegsomatropin drug product Product Code: ACP-011 INN or Proposed INN: LONAPEGSOMATRO ...	Ascendis Pharma Endocrinology Division A/S	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	240	Phase 3	Serbia;Belarus;United States;Slovakia;Greece;Spain;Ukraine;Israel;Italy;France;Australia;Denmark;Net ...
2	EUCTR2020-000929-42-DK (EUCTR)	05/08/2021	12/01/2021	Trial to compare the efficacy and safety of once-weekly lonapegsomatropin with placebo and a daily s ...	foresiGHt: A multicenter, randomized, parallel-arm, placebo- controlled (double- blind) and active-c ...	Adult Growth Hormone Deficiency (AGHD) MedDRA version: 20.0;Level: PT;Classification code 10056438;T ...	Product Name: lonapegsomatropin drug product Product Code: ACP-011 INN or Proposed INN: LONAPEGSOMATRO ...	Ascendis Pharma Endocrinology Division A/S	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	240	Phase 3	Serbia;Belarus;United States;Slovakia;Greece;Spain;Ukraine;Russian Federation;Israel;Italy;France;Au ...
3	ChiCTR2100048579	2021-08-01	2021-07-11	Efficacy and Safety of JINTROLONG for Transitional Growth Hormone Deficiency	Efficacy and Safety of JINTROLONG for Transitional Growth Hormone Deficiency (TGHD)	Transitional Growth Hormone Deficiency	Experimental group:polyethylene glycol recombinant human growth hormone injection;	The Children's Hospital of Zhejiang University School of Medicine	NULL	Pending		26	Both	Experimental group:23;	Phase 4	China
4	EUCTR2020-000929-42-DE (EUCTR)	09/06/2021	14/10/2020	Trial to compare the efficacy and safety of once-weekly lonapegsomatropin with placebo and a daily s ...	foresiGHt: A multicenter, randomized, parallel-arm, placebo- controlled (double- blind) and active-c ...	Adult Growth Hormone Deficiency (AGHD) MedDRA version: 20.0;Level: PT;Classification code 10056438;T ...	Product Name: lonapegsomatropin drug product Product Code: ACP-011 INN or Proposed INN: LONAPEGSOMATRO ...	Ascendis Pharma Endocrinology Division A/S	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	240	Phase 3	Japan;New Zealand;Germany;Bulgaria;Georgia;Romania;Poland;Canada;Armenia;United Kingdom;Turkey;Nethe ...
5	EUCTR2020-000929-42-ES (EUCTR)	21/04/2021	01/02/2021	Trial to compare the efficacy and safety of once-weekly lonapegsomatropin with placebo and a daily s ...	foresiGHt: A multicenter, randomized, parallel-arm, placebo- controlled (double- blind) and active-c ...	Adult Growth Hormone Deficiency (AGHD) MedDRA version: 20.0;Level: PT;Classification code 10056438;T ...	Product Name: lonapegsomatropin drug product Product Code: ACP-011 INN or Proposed INN: LONAPEGSOMATRO ...	Ascendis Pharma Endocrinology Division A/S	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	240	Phase 3	Serbia;Belarus;United States;Slovakia;Greece;Spain;Ukraine;Israel;Italy;France;Australia;Denmark;Net ...
6	EUCTR2020-000929-42-SK (EUCTR)	12/04/2021	24/11/2020	Trial to compare the efficacy and safety of once-weekly lonapegsomatropin with placebo and a daily s ...	foresiGHt: A multicenter, randomized, parallel-arm, placebo- controlled (double- blind) and active-c ...	Adult Growth Hormone Deficiency (AGHD) MedDRA version: 20.0;Level: PT;Classification code 10056438;T ...	Product Name: lonapegsomatropin drug product Product Code: ACP-011 INN or Proposed INN: LONAPEGSOMATRO ...	Ascendis Pharma Endocrinology Division A/S	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	240	Phase 3	Serbia;Belarus;United States;Slovakia;Greece;Spain;Ukraine;Russian Federation;Israel;Italy;France;Au ...
7	EUCTR2020-000929-42-GR (EUCTR)	23/03/2021	04/03/2021	foresiGHt: A multicenter, randomized, parallel-arm, placebo- controlled (double- blind) and active-c ...	foresiGHt: A multicenter, randomized, parallel-arm, placebo- controlled (double- blind) and active-c ...	Adult Growth Hormone Deficiency (AGHD) MedDRA version: 20.0;Level: PT;Classification code 10056438;T ...	Product Name: lonapegsomatropin drug product Product Code: ACP-011 INN or Proposed INN: LONAPEGSOMATRO ...	Ascendis Pharma Endocrinology Division A/S	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	240	Phase 3	Belarus;Serbia;United States;Slovakia;Greece;Spain;Ukraine;Israel;Russian Federation;Italy;France;De ...
8	EUCTR2020-000874-92-PL (EUCTR)	22/03/2021	26/10/2020	A Multicenter, 12-Month, Randomized, Open-Label, Active Control, Parallel Arm, Phase 2 Study of Dail ...	A Multicenter, 12-Month, Randomized, Open-Label, Active Control, Parallel Arm, Phase 2 Study of Dail ...	Growth hormone deficiency MedDRA version: 20.0;Level: PT;Classification code 10056438;Term: Growth h ...	Product Name: LUM-201 INN or Proposed INN: Ibutamoren mesilate Other descriptive name: IBUTAMOREN MESI ...	Lumos Pharma, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	80	Phase 2	United States;Poland;Ukraine;Australia;Russian Federation;Israel;New Zealand
9	NCT04633057 (ClinicalTrials.gov)	January 25, 2021	12/11/2020	A Study to Evaluating the Efficacy and Safety of Recombinant Long-acting Human Growth Hormone(TJ101) ...	A Phase III, Randomized, Open-label, Positive-controlled, Multi-center Study to Evaluating the Effic ...	Pediatric Growth Hormone Deficiency	Drug: TJ101;Drug: NordiFlex	I-Mab Biopharma Co. Ltd.	NULL	Recruiting	3 Years	12 Years	All	165	Phase 3	China
10	ChiCTR2000039505	2020-12-01	2020-10-30	An exploratory study of recombinant growth hormone in improving sexual dysfunction in male adult pat ...	An exploratory study of recombinant growth hormone in improving sexual dysfunction in male adult pat ...	Adult growth hormone deficiency	experimental group:Recombinant Human Growth Hormone;	Huashan Hospital Affiliated to Fudan University	NULL	Recruiting	18	50	Male	experimental group:20;		China

First Previous1 2 3 4 5…19Next Last

先頭へ

187. 歌舞伎症候群

臨床試験数 : 3 / 薬物数 : 8 - (DrugBank : 2) / 標的遺伝子数 : 3 - 標的パスウェイ数 : 15

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2012-000432-26-NL (EUCTR)	26/09/2012	27/03/2012	Prospective study on the metabolic and linear growth effects of growh hormone treatment in children ...	Prospective study on the metabolic and linear growth effects of growh hormone treatment in children ...	Kabuki Syndrome (KS, OMIM 147920) with a mutation in MLL2 gene. ;Therapeutic area: Body processes [G ...	Trade Name: Genotropin Product Name: Genotropin INN or Proposed INN: SOMATROPIN Other descriptive name: ...	Maastricht University Medical Centre	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			Netherlands

First Previous1Next Last

193. プラダー・ウィリ症候群

臨床試験数 : 111 / 薬物数 : 120 - (DrugBank : 30) / 標的遺伝子数 : 51 - 標的パスウェイ数 : 103

diseases per page:

Showing 1 to 3 of 3 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	ChiCTR2100046551	2021-05-18	2021-05-21	Multimodal magnetic resonance imaging changes in Prader-Willi syndrome before and after growth hormo ...	Application of multimodal magnetic resonance imaging in pre - and post-treatment evaluation of recom ...	Prader-Willi sydrome	Prader-Willi sydrome group treated with rhGH:Treat with rhGH;Prader-Willi sydrome group treated with ...	Cai Jinhua	NULL	Recruiting	0	16	Both	Prader-Willi sydrome group treated with rhGH:40;Prader-Willi sydrome group treated without rhGH:40;Normal development group:40;	N/A	China
2	NCT03554031 (ClinicalTrials.gov)	April 14, 2018	30/5/2018	A Study to Evaluate the Efficacy and Safety of Recombinant Human Growth HormoneInjection in Patients ...	A Single Arm, Multicenter Phase III Clinical Trial to Evaluate the Efficacy and Safety of Recombinan ...	Prader-Willi Syndrome	Drug: Recombinant Human Growth Hormone (rhGH) Injection	GeneScience Pharmaceuticals Co., Ltd.	Children's Hospital of Fudan University;Tongji medical college huazhong university of science & tech ...	Unknown status	1 Month	5 Years	All	30	Phase 3	China
3	EUCTR2017-002164-41-ES (EUCTR)	03/07/2017	21/06/2017	Study with adult patients with Prader-Willi syndrome, which evaluate the effect of growth hormone th ...	Growth hormone therapy in adults with Prader-Willi syndrome: Effect on muscle tone assessed by funct ...	Patients with Prader-Willi Syndrome (SPW) with Growth hormone deficit. MedDRA version: 20.0;Level: P ...	Trade Name: Genotonorm Miniquick 0,2 mg INN or Proposed INN: RECOMBINANT HUMAN GROWTH HORMON Other des ...	Fundació Parc Taulí	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes		Phase 4	Spain

First Previous1Next Last

265. 脂肪萎縮症

臨床試験数 : 116 / 薬物数 : 170 - (DrugBank : 61) / 標的遺伝子数 : 26 - 標的パスウェイ数 : 97

diseases per page:

Showing 1 to 10 of 12 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2007-003233-16-ES (EUCTR)	11/12/2007	22/10/2007	A multicenter, double-blind, randomized, placebo-controlled extension study assessing the efficacy a ...	A multicenter, double-blind, randomized, placebo-controlled extension study assessing the efficacy a ...	Lipodistrofia asociada a VIH.HIV-associated lipodystrophy. MedDRA version: 9.1;Level: LLT;Classifica ...	Product Name: Tesamorelin Product Code: TH9507 INN or Proposed INN: Tesamorelin Other descriptive name: ...	Theratechnologies Inc.	NULL	Not Recruiting			Female: yes Male: yes	300		United Kingdom;Belgium;France;Spain
2	EUCTR2007-003233-16-GB (EUCTR)	29/11/2007	02/08/2007	A Multicenter, Double-blind, Randomized, Placebo-Controlled Extension Study Assessing the Efficacy a ...	A Multicenter, Double-blind, Randomized, Placebo-Controlled Extension Study Assessing the Efficacy a ...	HIV-associated lipodystrophy MedDRA version: 9.1;Level: LLT;Classification code 10024608;Term: Lipod ...	Product Name: Tesamorelin Product Code: TH9507 INN or Proposed INN: Tesamorelin Other descriptive name: ...	Theratechnologies Inc.	NULL	Not Recruiting			Female: yes Male: yes	300	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (P ...	France;Spain;Belgium;United Kingdom
3	EUCTR2007-003233-16-FR (EUCTR)	19/09/2007	31/07/2007	A Multicenter, Double-blind, Randomized, Placebo-Controlled Extension Study Assessing the Efficacy a ...	A Multicenter, Double-blind, Randomized, Placebo-Controlled Extension Study Assessing the Efficacy a ...	HIV-associated lipodystrophy MedDRA version: 9.1;Level: LLT;Classification code 10024608;Term: Lipod ...	Product Name: Tesamorelin Product Code: TH9507 INN or Proposed INN: Tesamorelin Other descriptive name: ...	Theratechnologies Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	300		United Kingdom;Belgium;France;Spain
4	EUCTR2007-003233-16-BE (EUCTR)	05/09/2007	22/08/2007	A Multicenter, Double-blind, Randomized, Placebo-Controlled Extension Study Assessing the Efficacy a ...	A Multicenter, Double-blind, Randomized, Placebo-Controlled Extension Study Assessing the Efficacy a ...	HIV-associated lipodystrophy MedDRA version: 9.1;Level: LLT;Classification code 10024608;Term: Lipod ...	Product Name: Tesamorelin Product Code: TH9507 INN or Proposed INN: Tesamorelin Other descriptive name: ...	Theratechnologies Inc.	NULL	Not Recruiting			Female: yes Male: yes	300		United Kingdom;Belgium;France;Spain
5	EUCTR2006-005444-88-DE (EUCTR)	21/06/2007	14/08/2007	A Multicenter, Double-blind, Randomized, Placebo-Controlled Study Assessing the Efficacy and Safety ...	A Multicenter, Double-blind, Randomized, Placebo-Controlled Study Assessing the Efficacy and Safety ...	HIV-associated lipodystrophy MedDRA version: 8.1;Level: LLT;Classification code 10024608;Term: Lipod ...	Product Name: TH9507 Product Code: TH9507 Other descriptive name: [N-trans-3-Hexenoyl] Human Growth Ho ...	Theratechnologies Inc.	NULL	Not Recruiting			Female: yes Male: yes	400		United Kingdom;Germany;France;Spain
6	EUCTR2006-005444-88-GB (EUCTR)	08/05/2007	26/01/2007	A Multicenter, Double-blind, Randomized, Placebo-Controlled Study Assessing the Efficacy and Safety ...	A Multicenter, Double-blind, Randomized, Placebo-Controlled Study Assessing the Efficacy and Safety ...	HIV-associated lipodystrophy MedDRA version: 8.1;Level: LLT;Classification code 10024608;Term: Lipod ...	Product Name: TH9507 Product Code: TH9507 Other descriptive name: [N-trans-3-Hexenoyl] Human Growth Ho ...	Theratechnologies Inc.	NULL	Not Recruiting			Female: yes Male: yes	400	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (P ...	France;Spain;Belgium;Germany;United Kingdom
7	EUCTR2006-005444-88-ES (EUCTR)	25/04/2007	03/03/2010	A Multicenter, Double-blind, Randomized, Placebo-Controlled Study Assessing the Efficacy and Safety ...	A Multicenter, Double-blind, Randomized, Placebo-Controlled Study Assessing the Efficacy and Safety ...	HIV-associated lipodystrophyLipodistrofia asociada al VIH MedDRA version: 8.1;Level: LLT;Classificat ...	Product Name: TH9507 Product Code: TH9507 Other descriptive name: [N-trans-3-Hexenoyl] Human Growth Ho ...	Theratechnologies Inc.	NULL	Not Recruiting			Female: yes Male: yes	400		Germany;United Kingdom;France;Spain
8	EUCTR2006-005444-88-FR (EUCTR)	15/02/2007	11/01/2007	A Multicenter, Double-blind, Randomized, Placebo-Controlled Study Assessing the Efficacy and Safety ...	A Multicenter, Double-blind, Randomized, Placebo-Controlled Study Assessing the Efficacy and Safety ...	HIV-associated lipodystrophy MedDRA version: 8.1;Level: LLT;Classification code 10024608;Term: Lipod ...	Product Name: TH9507 Product Code: TH9507 Other descriptive name: [N-trans-3-Hexenoyl] Human Growth Ho ...	Theratechnologies Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	400		Germany;United Kingdom;France;Spain
9	EUCTR2006-005444-88-BE (EUCTR)	16/01/2007	21/12/2006	A Multicenter, Double-blind, Randomized, Placebo-Controlled Study Assessing the Efficacy and Safety ...	A Multicenter, Double-blind, Randomized, Placebo-Controlled Study Assessing the Efficacy and Safety ...	HIV-associated lipodystrophy MedDRA version: 8.1;Level: LLT;Classification code 10024608;Term: Lipod ...	Product Name: TH9507 Product Code: TH9507 Other descriptive name: [N-trans-3-Hexenoyl] Human Growth Ho ...	Theratechnologies Inc.	NULL	Not Recruiting			Female: yes Male: yes	400		France;Spain;Belgium;Germany;United Kingdom
10	NCT00130286 (ClinicalTrials.gov)	March 2005	12/8/2005	Growth Hormone and/or Rosiglitazone for HIV-Associated Increased Abdominal Fat and Insulin Resistanc ...	Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Recombinant Human G ...	HIV-Associated Lipodystrophy Syndrome;Insulin Resistance;HIV Infections;Metabolic Syndrome X;Body We ...	Drug: Rosiglitazone;Drug: Recombinant human growth hormone + rosiglitazone	Weill Medical College of Cornell University	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Completed	18 Years	65 Years	All	77	Phase 1/Phase 2	United States

First Previous1 2Next Last

先頭へ